BTN1A1 and neoplasm: In this context, the discovery of BTN as an immunoregulatory molecule involved in Vδ2 T cell activation led to the development of Imcheck ICT01, an activating humanized IgG1 Ab, which, upon binding to BTN3A, triggers Vδ2 T cell activation and increased cytotoxicity against BTN-expressing tumor cells.